Creating RNAi synergy

MDRNA is a powerful partner for pharmaceutical and biotechnology companies, academic institutions, and research foundations who are interested in RNAi-based therapeutics and their potential for providing safe and effective treatment for a wide variety of diseases. We place a high value on relationships that will provide us the opportunity to expand our internal research and development programs through access to new technologies and therapeutic programs.

Working closely with leading biotechnology and pharmaceutical companies, we can accelerate product opportunities that will ultimately benefit patients and partners alike. Our capabilities in cellular biology, peptide and lipid chemistry, bioinformatics, and our strong IP position provide partners with the ability to rapidly move RNAi product candidates from target selection to IND in a 12 to 18 month timeframe. All 20,000 human genes are available for development through our patent estate enabling us to pursue any disease target of our choosing without the need to obtain licenses to existing patents.